Modern Retina Staff

A poll for retina specialists regarding their preference on attending specialty conferences and meetings. This poll is closed.

Investigators at Dartmouth College have found that eye contact during a conversation makes the discussion more appealing to its participants.

A synopsis of the findings presented at EURETINA 2021 for ophthalmologists and retina specialists.

Quan Dong Nguyen, MD, MSc, FARVO, FASRS, speaks on the highlights of his presentation regarding new biological treatments of posterior uveitis.

Mark Breazzano, MD, discusses his views on the future of telehealth for ophthalmologists and retina specialists.

Mark Breazzano, MD, discusses his research into the decrease in urgent and emergent procedures in ophthalmology, how he's handling it in his practice, and how to make patients more comfortable coming in to receive care.

Dr. Mark Breazzano discusses the impact of COVID-19 on his practice and how patients are reacting.

Approval may inspire increased vaccination effort.

Mark Breazzano, MD, discusses the future of retina specialists' practice within context of the ongoing pandemic.

Programming includes 16 EURETINA sessions; 22 symposia; 44 instructional courses; 85 hours of content, and more than 300 speakers.

Dr. Mark Breazzano discusses pandemic-related patient hesitancy and how retina specialists can help.

Despite setbacks in DME, Adverum Biotechnologies said it will continue to develop ADVM-022 for wet AMD.

Outlook Therapeutics completes Phase 3 NORSE TWO safety and efficacy trial for ONS-5010, an investigational ophthalmic formulation of bevacizumab for treatment of wet AMD.

Mark Breazzano, MD, discusses the future of telehealth for retina specialists.

The U.S. FDA granted orphan drug designation to ADX-2191, methotrexate for intravitreal injection, as treatment for retinitis pigmentosa.

If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

A team of investigators used corneal confocal microscopy to identify corneal nerve damage in cases of long COVID-19.

The American Society of Cataract and Refractive Surgery hosted its 2021 ASCRS and ASOA Annual Meeting July 23-27 in Las Vegas, Nevada.

Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.

Mark Breazzano, MD, discusses the effects of the COVID-19 pandemic on daily practice for retina specialists.

A team of investigators found that the retina may offer signs of COVID-19 infection before symptoms present.

A poll for ophthalmologists and retina specialists to celebrate UV Safety Month. This poll will close July 28, 2021.

As the Fourth of July approaches, ophthalmologists warn patients to exercise caution with fireworks.

A survey of fireworks-related injuries for ophthalmologists and retina specialists.

According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.

Standardization of Uveitis Nomenclature (SUN) Working Group utilized machine learning to create new uveitis classification criteria, inciting hope for implementation in clinical and research settings.

The not-for-profit vision and healthcare organization breaks ground on premier Technology Center for assistive technology for people with vision loss.

PDUFA action date of October 30, 2021, is assigned for investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.

The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.

Members of the medical community gather virtually to discuss current issues in the field, public health, and general business.